Vol. 1 No. 2 (2024): SMART-MD Journal of Precision Medicine (Summer 2024)

Summer 2024 Issue Spotlight: Pancreatic Diseases and Pharmacogenetics

Precision Medicine tailors treatment to match an individual's genetics, risk factors, and biomarkers, ensuring the correct treatment, dose, and timing, including pharmacogenetics for drug dosing.

Acute and Chronic Pancreatitis: Biomarkers in acute pancreatitis (AP) require quick decisions within 24 hours.  The consensus article by Lee et al. gives clinical decision support guidance for early management of AP. For chronic pancreatitis, C. Mel Wilcox discusses the use of fecal elastase (FE1) for accurately diagnosing EPI, while Andrea Geisz explains interpreting complex PRSS1 genetic results.

Pharmacogenetics (PGx): Essential across all medical treatments, PGx involves tailoring treatments based on genetic makeup. Experts Yang and Luzum highlight PGx considerations for beta-blockers, offering practical applications.